key: cord-0694968-l604jgte
authors: Lo, Michael K.; Jordan, Paul C.; Stevens, Sarah; Tam, Yuen; Deval, Jerome; Nichol, Stuart T.; Spiropoulou, Christina F.
title: Susceptibility of paramyxoviruses and filoviruses to inhibition by 2′-monofluoro- and 2′-difluoro-4′-azidocytidine analogs
date: 2018-03-27
journal: Antiviral Res
DOI: 10.1016/j.antiviral.2018.03.009
sha: 76334d2eb2d9325ec6021ed312e35321b964e04f
doc_id: 694968
cord_uid: l604jgte

Ebolaviruses, marburgviruses, and henipaviruses are zoonotic pathogens belonging to the Filoviridae and Paramyxoviridae families. They exemplify viruses that continue to spill over into the human population, causing outbreaks characterized by high mortality and significant clinical sequelae in survivors of infection. There are currently no approved small molecule therapeutics for use in humans against these viruses. In this study, we evaluated the antiviral activity of the nucleoside analog 4′-azidocytidine (4′N(3)-C, R1479) and its 2′-monofluoro- and 2′-difluoro-modified analogs (2′F-4′N(3)-C and 2′diF-4′N(3)-C) against representative paramyxoviruses (Nipah virus, Hendra virus, measles virus, and human parainfluenza virus 3) and filoviruses (Ebola virus, Sudan virus, and Ravn virus). We observed enhanced antiviral activity against paramyxoviruses with both 2′diF-4′N(3)-C and 2′F-4′N(3)-C compared to R1479. On the other hand, while R1479 and 2′diF-4′N(3)-C inhibited filoviruses similarly to paramyxoviruses, we observed 10-fold lower filovirus inhibition by 2′F-4′N(3)-C. To our knowledge, this is the first study to compare the susceptibility of paramyxoviruses and filoviruses to R1479 and its 2′-fluoro-modified analogs. The activity of these compounds against negative-strand RNA viruses endorses the development of 4′-modified nucleoside analogs as broad-spectrum therapeutics against zoonotic viruses of public health importance.

In the decades prior to 2014, human outbreaks of emerging zoonotic viruses causing fatal hemorrhagic fever, such as Ebola virus (EBOV), or encephalitis, such as Nipah virus (NiV), have been relatively sporadic and small in terms of case numbers, ranging from isolated single cases to several hundred cases (CDC, 2017; Luby and Gurley, 2012) . The historically largest EBOV outbreak of 2013-2016 highlighted the relative paucity of efficacious therapeutics and vaccines available to deploy against such pathogens, despite extensive pre-clinical studies demonstrating efficacy of therapeutic antibodies and vaccines for these biosafety level-4 pathogens (Broder et al., 2016; Geisbert et al., 2014; Mendoza et al., 2017; Mire et al., 2016; Qiu et al., 2014) . To identify therapeutics that could be repurposed against EBOV, in vitro screens of libraries of FDA-approved compounds have been conducted, screening, among others, antiviral nucleoside and nucleotide analogs (Madrid et al., 2015; Veljkovic et al., 2015; Welch et al., 2016) . Over the last 30 years, the development of antiviral nucleoside and nucleotide analogs was primarily directed towards combating viruses responsible for chronic infections such as human immunodeficiency virus, herpes viruses, and hepatitis viruses (Ray and Hitchcock, 2009 ). In 2006, Klumpp and colleagues first demonstrated the in vitro activity of 4′azidocytidine (4′N 3 -C, R1479) against hepatitis C virus (HCV), a singlestranded, positive-sense RNA virus (Klumpp et al., 2006) . The development of R1479 and its prodrug balapiravir was halted following findings of toxicity and low efficacy of these compounds in clinical trials for treating HCV and Dengue virus (Nelson et al., 2012; Nguyen et al., 2013) . Despite this, the in vitro activity of R1479 against diverse flaviviruses of public health importance, such as Dengue virus and tickborne encephalitis virus, suggested that it may be a template for developing modified analogs with antiviral activity Eyer et al., 2016) . Interestingly, R1479 and other 4′-modified analogs have recently been shown to also inhibit respiratory syncytial virus (RSV), a single-stranded, negative-sense RNA virus (Clarke et al., 2015; Deval et al., 2015; Wang et al., 2015) . Following those studies, we described potent antiviral activity of R1479 against representative members of the Paramyxoviridae family, including the henipaviruses, NiV and Hendra virus (HeV) . Given the in vitro antiviral properties of R1479 and its 2′-mono and 2′-difluoro analogs (2′F-4′N 3 -C and 2′diF-4′N 3 -C, respectively) against RSV , and the highly conserved nucleotide binding domains shared across Pneumoviridae, Paramyxoviridae, and Filoviridae families , we evaluated and compared the antiviral potencies of these cytidine analogs against representative paramyxoviruses and filoviruses including the 2014 Makona variant of EBOV (Albarino et al., 2015) . Our study documents the susceptibility of paramyxoviruses and filoviruses to R1479 and its 2′-fluoro-modified analogs, and reinforces the prospect of developing 4′-modified nucleoside analogs as potential broad-spectrum therapeutics against RNA viruses of public health importance.

All work with infectious virus was performed in Class 2 Biosafety cabinets, and all work utilizing live Nipah virus (NiV), Hendra virus (HeV), Ebola virus (EBOV), Sudan virus (SUDV), Ravn virus (RAVV), Marburg virus (MARV), and Rift Valley Fever virus (RVFV) was conducted in a BSL-4 laboratory at the Centers for Disease Control and Prevention (CDC; Atlanta, GA).

HeLa, SK-N-MC, and NCI-H358 cells were purchased from the American Type Tissue Culture Collection (ATCC, Manassas, VA, USA). HeLa and SK-N-MC cells were propagated in Dulbecco's modified Eagle medium (DMEM; Life Technologies, Carlsbad, CA, USA) supplemented with 10% (vol/vol) fetal calf serum (FCS; Hyclone; Thermo Scientific, Waltham, MA, USA) and penicillin-streptomycin (Life Technologies). NCI-H358 cells were propagated in Roswell Park Memorial Institute medium (RPMI 1640), supplemented with 10% FCS. Huh7 cells were obtained from Apath, LLC (Brooklyn, NY, USA), and propagated in DMEM supplemented with 10% FCS and 1× nonessential amino acids (Life Technologies). Normal human small airway epithelial cells (SAECs) were purchased from ATCC and propagated in Airway Epithelial Cell Basal medium supplemented with the Bronchial Epithelial Cell Growth Kit (ATCC).

NiV (Malaysian genotype), recombinant NiV Malaysian genotype expressing ZsGreen1 fluorescent protein (NiV-GFP2AM) (Lo et al., 2014) , HeV, recombinant Measles virus (MV) (Edmonston-Zagreb strain) expressing enhanced green fluorescent protein) (rMV EZ EGFP (3)) (Rennick et al., 2015) , EBOV (Makona variant), recombinant EBOV (Mayinga variant) (representative of Ebolavirus genus), SUDV (Gulu variant) (Sanchez and Rollin, 2005) , RAVV (Ravn variant) (Johnson et al., 1996) , and recombinant RVFV expressing enhanced green fluorescent protein (RVFV-GFP, ZH501) (Bird et al., 2007) were propagated in either Vero E6 (ATCC CRL-1586) or Vero (ATCC CCL-81) cells, and were quantitated by 50% tissue culture infections dose (TCID 50 ) assay using the Reed and Muench method (Reed and Muench, 1938) . Recombinant EBOV Makona variant expressing ZsGreen1 (EBOV-ZsG) (Albarino et al., 2015) and recombinant MARV (Bat371 variant) expressing ZsGreen1 (MARV-ZsG) was propagated and quantitated as above using Huh7 cells. Recombinant respiratory syncytial virus (RSV) expressing enhanced green fluorescent protein (rgRSV224) (Hallak et al., 2000) was propagated and quantitated as above using HeLa cells. Recombinant human parainfluenza virus 3 expressing enhanced green fluorescent protein (hPIV3-GFP) (JS strain) (Zhang et al., 2005) was obtained from ViraTree and was propagated and quantitated as above using Vero cells.

R1479, 2′F-4′N 3 -C, 2′diF-4′N 3 -C ( Fig. 1) and their corresponding triphosphates were synthesized at Alios BioPharma.

Recombinant RSV L-P was produced through the co-expression of RSV L and P proteins in a baculovirus expression system, according to previously described procedures (Noton et al., 2012) . The reaction mixture was composed of 0.2 μM modified template sequence (UGCG CUUGUUU), 0.2 μM recombinant RSV L-P polymerase, 200 μM 5′-pACGC primer, buffer (20 mM Tris pH 7.5, 10 mM KCl, 6 mM MgCl2, 2 mM DTT, 0.01% Triton, 10% DMSO), and (α-33 P)-GTP with a final volume of 10 μL. The reaction was started through the addition of NTPs, incubated at 30°C for 30 min, and quenched through the addition of gel loading buffer (Ambion). Samples were run for 1.5 h at 80 W in a 22.5% polyacrylamide urea sequencing gel. The gel was then exposed to a phosphor-screen, and scanned.

R1479 triphosphate (TP) formation was measured in HeLa, Huh7, SK-N-MC, and NCI-H358 cells. 2′F-4′N 3 -CTP, and 2′diF-4′N 3 -CTP formation were measured in HeLa and NCI-H358 only. The cells were maintained and cultured at Alios BioPharma. The cells were seeded in six-well plates at 1.5 × 10 6 cells/well with their corresponding media and incubated overnight in a cell culture incubator at 37°C and 5% CO 2 before use. In the experiment, 50 μM of R1479, 2′F-4′N 3 -C, or 2′diF-4′N 3 -C was added to each well, incubated for 24 h at 37°C and 5% CO 2 . At the end of the incubation, the medium was removed and cells were washed twice with cold 0.9% sodium chloride in water. The cells were lysed with methanol/water (70%/30%, v/v), and the extracted supernatant was dried and reconstituted in 1 mM ammonium phosphate before LC/MS/MS analysis to determine the corresponding R1479-TP, 2′F-4′N 3 -CTP, and 2′diF-4′N 3 -CTP levels (Chen et al., 2009 ). The concentrations of the R1479-TP, 2′F-4′N 3 -CTP, and 2′diF-4′N 3 -CTP were normalized by the number of cells and reported as picomoles per million cells.

All viruses expressing fluorescent (GFP, ZsGreen) proteins were assayed for fluorescence by using an H1 Synergy plate reader (Biotek). NCI-H358 cells or SAECs were seeded at 2 × 10 4 cells per well in black opaque 96-well plates (Corning 3619, Corning, NY) or Perkin-Elmer CellCarrier Ultra plates (Waltham, MA) and compounds were added to the assay plates for 1 h. Assay plates were transferred to the BSL-4 suite (where appropriate), and infected with 0.25-0.5 TCID 50 per cell of the respective virus, and were read between 48 and 168 h post-infection (hpi) depending on the virus used. Fluorescence signal from DMSOtreated infected cells were set as 100% GFP. 50% effective concentrations (EC 50 ) were calculated using four-parameter variable slope nonlinear regression fitting of mean values of assays performed in quadruplicate (Graphpad Prism 6, La Jolla, CA).

NCI-H358 cells or SAECs were seeded at 2 × 10 4 cells per well in white opaque 96-well plates, and compounds were added to the assay plates. Assay plates were transferred to the BSL-4 suite and infected with 0.25-0.5 TCID 50 per cell, and were analyzed with CellTiter-Glo 2.0 (Promega, Madison, WI) between 72 and 96 h post-infection (pi) in a HD1 Synergy plate reader. Values were normalized to uninfected cell controls according to % viability as follows: % viability = [(specific value-reference value)/(DMSO control valuereference value)] × 100. Reference values were derived from control wells without cells. Uninfected cell control values (after subtraction of reference values) were set at 100% inhibition of CPE. EC 50 values were calculated using four-parameter variable slope non-linear regression fitting of values. The CellTiter-Glo 2.0 assay was also used to determine viability of uninfected NCI-H358 cells treated with 3-fold serial dilutions of the compounds for 72 h (3 days) or 168 h (7 days). Values were normalized to DMSO controls according to % viability as follows: % viability = [(specific value-reference value)/(DMSO control valuereference value)] × 100. Reference values were derived from control wells without cells. DMSO control values (after subtraction of reference values) were set at 100% viability. 50% viability/cytotoxicity (CC 50 ) values were calculated using four-parameter variable slope non-linear regression fitting of mean values derived from quadruplicate samples.

To measure compound inhibition of filovirus infection and spread, 2 × 10 4 NCI-H358 cells or SAECs treated with compound were infected with 0.5 TCID 50 of EBOV, SUDV, RAVV, or MARV-ZsG. At 7 days pi, cells were fixed in 10% formalin supplemented with 0.2% Triton-X detergent, and stained with primary rabbit anti-EBOV polyclonal serum (1:2000), and after several washes the corresponding anti-rabbit Dylight 488 conjugated secondary antibody (Bethyl Laboratories, Bethesda, MD) was added (1:1000) for 1 h. After 3 washes, filovirus infection-induced focus forming units (FFU) were measured in each well of the 96-well plate (CellCarrier-96, Perkin Elmer, Waltham, MA) using a Cytation5 cell imaging multi-mode reader paired with Gen5 software (Biotek, Winooski, VT). For MARV-ZsG, GFP+ cells were counted directly at 3 days pi without need for fixation and antibody staining. A 2.74× objective lens was used to take 12 overlapping images encompassing each entire well, which were assembled and then analyzed for FFUs ranging in size from 15-200 μm, and which had a relative fluorescence signal that was above 2000. The camera gain was set at 15.6, with an integration time of 306 msec, using an LED intensity setting of 10. The average number of background cell counts were subtracted from each well to give normalized cells counts, and any negative values were adjusted to "0". For analysis of each experimental replicate, the highest number of positive counts was regarded as 100%, while 0 counts was used for 0% positivity. Following this normalization, data were fitted to a 4-parameter variable slope non-linear regression fitting of mean values derived from quadruplicate samples.

To measure compound inhibition of infectious filovirus yield, 2 × 10 4 NCI-H358 cells were infected with 0.5 TCID 50 of SUDV or RAVV per cell for 1 h. Virus inoculum was then removed, cells were washed once with phosphate buffered saline, and replaced with culture medium containing respective compound in a 10-point 3-fold dilution series. At 7 days pi, supernatants were harvested, serially diluted (10fold) and mixed with 10 4 Vero cells per well in 96 well plates. At day 5 pi, plates were fixed with 10% formalin supplemented with 0.2% Triton-X detergent, and stained with primary rabbit anti-EBOV serum, and after several washes the corresponding anti-rabbit Dylight 488 conjugated secondary antibody was added. Plates were visually assayed using a microscope for fluorescent cells, and quantitated by 50% tissue TCID 50 assay using the Reed and Muench method (Reed and Muench, 1938) . EC 50 values were calculated using four-parameter variable slope non-linear regression fitting of mean values derived from quadruplicate samples. Similarly, to measure compound inhibition of infectious henipavirus yield, 2 × 10 4 NCI-H358 cells were infected with 0.25 TCID 50 of NiV or HeV per cell for 1 h. Virus inoculum was then removed, cells were washed once with phosphate buffered saline, and replaced with culture medium containing compound in a 10-point 3-fold dilution series. At 48 h pi supernatants were harvested, serially diluted, and mixed with 10 4 Vero cells per well in 96-well plates. At day 5 pi, plates were visually assayed for CPE, and then virus titers were quantitated by 50% tissue TCID 50 assay using the Reed and Muench method (Reed and Muench, 1938) . EC 50 values were calculated using four-parameter variable slope non-linear regression fitting of mean values derived from quadruplicate samples.

To confirm the antiviral mechanism of action of R1479 and its 2′mono and 2′-difluoro-modified analogs (depicted in Fig. 1a , b, and c respectively), we first performed cell-free in vitro RSV polymerase assays. The RSV polymerase forms a dimer of the L and P protein (RSV L-P) that accepts RNA templates with a primer to generate short RNA synthesis products (Fig. 1d) (Noton et al., 2012) . RSV L-P extends the primer by 1 base with the addition of (α-33 P)-GTP (Fig. 1e , lane 1) and fully it extends by 7 bases with the addition of ATP and CTP (Fig. 1e , lane 3). We individually substituted the 3 cytidine analogs in place of natural CTP to understand their potential effects as non-obligatory chain terminators in an RNA synthesis assay (Fig. 1e, lanes 4-6) . R1479-TP, 2′F-4′N 3 -CTP, and 2′diF-4′N 3 -CTP terminated RNA synthesis by RSV L-P at position +8, and were recognized almost equally by the enzyme. This is consistent with observations of other 2′ and 4′-modified cytidine analogs that inhibit RSV polymerase in similar assays .

3.2. Intracellular phosphorylation levels of R1479, 2′F-4′N 3 -C, and 2′diF-4′N 3 -C are highly dependent on cell type

In a previous study, we observed different levels of R1479 antiviral activity against henipaviruses depending on the cell line used, with consistently lower R1479 antiviral activity in HeLa cells than in a human epithelial lung carcinoma cell line (NCI-H358) . To investigate whether this difference was due to cellular phosphorylation levels of R1479, we measured intracellular phosphorylation of R1479 in 4 human cell lines: HeLa, a cervical adenocarcinoma line; Huh7, a hepatoma line; SK-N-MC, a neuroepithelioma line; and NCI-H358. Each cell line was treated with R1479 for 24 h, and intracellular triphosphate levels were then measured using tandem liquid chromatography/mass spectrometry (LC/MS/MS) and quantitated using synthetic standards. Levels of the corresponding triphosphate (R1479-TP) were measured in each of the 4 cell lines, with highest R1479-TP levels seen in NCI-H358 cells (391 ± 72 pmol/million cells; Fig. 2a ). Phosphorylation of R1479 was lowest in Huh7 cells and SK-N-MC cells (18 ± 0.6 and 42 ± 10 pmol/million cells, respectively), and In addition to R1479, which contains a 4′-azido substitution, we examined the effects of 2′-monofluoro or 2′-difluoro substitutions on NTP levels using the 2 cell lines with the highest NTP levels. HeLa and NCI-H358 cells were treated with 2′F-4′N 3 -C and 2′diF-4′N 3 -C for 24 h at 50 μM, and NTP formation was measured and quantified as previously described (Fig. 2b) . In both cell lines, 2′diF-4′N 3 -C levels were highest, followed by R1479 and then 2′F-4′N 3 -C, but higher overall NTP levels of all 3 nucleosides were seen in NCI-H358 cells. In light of these results, we decided to use NCI-H358 cells for our cell-based viral infection assays.

3.3. R1479, 2′F-4′N 3 -C, and 2′diF-4′N 3 -C show minimal cytotoxicity in NCI-H358 cells

To ensure that the antiviral effects we observed in this study were not due to any cytotoxic effects attributed to the compounds themselves, we measured the viability of NCI-H358 cells continually incubated with varying dilutions of each compound for 3 and 7 days (Fig. 3) . All 3 compounds produced low cytotoxicity 3 days post treatment, and R1479 and 2′diF-4′N 3 -C resulted only in mild cytotoxicity at the highest concentration used (100 μM) after 7 days of treatment (Fig. 4b ). Even 7 days post treatment, 50% cell cytotoxicity (CC 50 ) levels were not reached.

3.4. 2′F-4′N 3 -C and 2′diF-4′N 3 -C show superior antiviral activity compared to R1479 against recombinant reporter NiV, RSV, measles virus, and human parainfluenza virus 3

We initially evaluated the antiviral activity of R1479, 2′F-4′N 3 -C, and 2′diF-4′N 3 -C against recombinant reporter RSV (rgRSV224; (Hallak et al., 2000) , measles virus (rMV EZ EGFP(3); (Rennick et al., 2015) , human parainfluenza virus-3 (hPIV3-GFP; (Zhang et al., 2005) , and NiV (NiV-GFP2AM (Lo et al., 2014) , expressing green fluorescent reporter proteins (Fig. 4) . Whereas EC 50 values for R1479 against all 4 viruses were consistently in the single-digit micromolar range, both 2′F-4′N 3 -C and 2′diF-4′N 3 -C inhibited each virus 3-to 20-fold more potently than R1479 (Table 1) . 2′F-4′N 3 -C and 2′diF-4′N 3 -C inhibited rgRSV224 and rMV EZ EGFP(3) at similar concentrations (Table 1) , but 2′F-4′N 3 -C was measurably more potent than 2′diF-4′N 3 -C against hPIV3-GFP (Fig. 4c , Table 1 ). 2′F-4′N 3 -C also inhibited NiV-GFP2AM moderately more strongly than 2′diF-4′N 3 -C as measured by both a GFP reporter assay (Fig. 4d) and CPE inhibition assay (data not shown; Table 1 ).

We further evaluated the antiviral activity of 2′F-4′N 3 -C and 2′diF-4′N 3 -C against wild-type NiV and HeV by measuring the inhibition of henipavirus-induced CPE and infectious virus yield (Fig. 5) . Similar to what was observed for NiV-GFP2AM, 2′F-4′N 3 -C and 2′diF-4′N 3 -C inhibited NiV-and HeV-induced CPE with significantly greater potency than R1479, with 2′F-4′N 3 -C being marginally more potent than 2′diF-4′N 3 -C ( Fig. 5a and b) . Accordingly, ∼1.5 μM 2′F-4′N 3 -C and ∼3 μM 2′diF-4′N 3 -C reduced infectious henipavirus yields by 4-5 orders of magnitude ( Fig. 5c and d) , whereas 6-10 μM R1479 was required for similar virus yield reduction . Although in this assay, EC 50 values for 2′F-4′N 3 -C and 2′diF-4′N 3 -C were identical against HeV and were within 3-fold against NiV (Table 1) , 2′F-4′N 3 -C caused a sharper decline in both NiV and HeV titers than did 2′diF-4′N 3 -C ( Fig. 5c and d) .

3.6. EBOV variants are susceptible to inhibition by R1479 and 2′diF-4′N 3 -C, but are less susceptible to 2′F-4′N 3 -C inhibition Recent work describing the broad-spectrum activity of adenosine nucleotide analog GS-5734 across Paramyxoviridae, Pneumoviridae, and Filoviridae families documented conserved amino acids in the nucleotide-binding domains of polymerases of these viruses, which may explain their susceptibility to similar compounds . In light of this work, alongside other studies documenting the antiviral activity of R1479, 2′F-4′N 3 -C, and 2′diF-4′N 3 -C against both HCV and RSV Klumpp et al., 2006; Smith et al., 2007 Smith et al., , 2009 Wang et al., 2015) , we tested the antiviral activities of these compounds against recombinant reporter Mayinga and Makona EBOV variants (genus Ebolavirus, species Zaire ebolavirus) expressing green fluorescent proteins (Albarino et al., 2015; Towner et al., 2005) (Fig. 6a and b) . R1479 and 2′diF-4′N 3 -C inhibited both EBOV variants similarly to henipaviruses, with approximate EC 50 values of 2 μM and 0.3 μM, respectively (Table 1 ). In contrast to what was observed for henipaviruses, however, 2′F-4′N 3 -C was 10 times less potent against EBOV, with EC 50 values ranging from 3-8 μM (Table 1) . All 3 compounds only negligibly inhibited a reporter RVFV, which belongs to the family Phenuiviridae, outside of the order Mononegavirales (Fig. 6c) .

To confirm our observations, we tested the compounds against wildtype EBOV (Makona variant) and measured their inhibition of EBOV infection and spread. By using an image-based plate reader, we quantified EBOV infection by the percentage of EBOV antigen-positive focus-forming units (FFUs) detected ( Fig. 6d-e) . We observed dosedependent inhibition of FFU formation with R1479 and 2′diF-4′N 3 -C treatment, but did not detect significant inhibition by 2′F-4′N 3 -C (Fig. 6d, Table 1 ).

We then tested the 3 compounds against the Gulu variant of SUDV (genus Ebolavirus, species Sudan ebolavirus), a phylogenetically divergent relative of EBOV which prior to 2014 was responsible for the largest filovirus outbreak in humans (Lamunu et al., 2004; Sanchez and Rollin, 2005) . R1479 and 2′diF-4′N 3 -C inhibited SUDV with efficacy similar to that observed with EBOVs by the FFU assay (Fig. 7a) , with EC 50 values of 2.5 μM (R1479) and 0.7 μM (2′diF-4′N 3 -C). Accordingly, 2′F-4′N 3 -C inhibited SUDV less potently than the other compounds, with an EC 50 value of approximately 10 μM (Table 1) . We further evaluated the antiviral activity of these 3 cytidine analogs against SUDV by measuring infectious virus yield (Fig. 7b) . Both R1479 and 2′diF-4′N 3 -C reduced infectious SUDV titers by > 4 orders of magnitude at concentrations of 25 μM and 6.25 μM, respectively, with respective EC 50 values of 0.92 μM and 0.16 μM. On the other hand, 2′F-4′N 3 -C only reduced infectious virus yield by approximately 1.5 orders of magnitude at the highest concentration used in the assay (12.5 μM) (Fig. 7b) .

Having determined the antiviral activity of these compounds against phylogenetically divergent members of the genus Ebolavirus, we proceeded to test them against another filovirus, Ravn virus (RAVV) (genus Marburgvirus, species Marburg marburgvirus), which, when compared with EBOV and SUDV, was determined to be the most phylogenetically divergent member of the genus Marburgvirus (∼67-68% nucleotide divergence) (Towner et al., 2006) . Using our FFU assay, we observed that R1479 inhibited RAVV with 3-fold lower potency than EBOV or SUDV, with an EC 50 value of 7.4 μM (Fig. 8a, Table 1 ). 2′diF-4′N 3 -C and 2′F-4′N 3 -C, however, inhibited RAVV similarly to EBOV and SUDV, with EC 50 values of 0.73 μM and 10.8 μM, respectively. We then measured infectious RAVV production in the presence of the 3 compounds. Similar to what we observed for SUDV, both R1479 and 2′diF-4′N 3 -C reduced infectious RAVV titers by over 4 orders of magnitude at concentrations of 50 μM and 6.25 μM, respectively, with respective EC 50 values of 3 μM (R1479) and 0.16 μM (2′diF-4′N 3 -C; Fig. 8b , Table 1 ). 2′F-4′N 3 -C reduced RAVV titers by roughly 1.5 orders of magnitude at the highest concentration used (25 μM), with an EC 50 value of 6 μM (Fig. 8b, Table 1 ).

To verify the antiviral activity observed in the NCI-H358 cell line, we performed reporter and CPE assays for NiV using human primary Fig. 5 . R1479, 2′F-4′N 3 -C, and 2′diF-4′N 3 -C reduce henipavirus cytopathic effect (CPE) and infectious virus yield. Representative dose response curves for R1479 (green circles), 2′F-4′N 3 -C (blue triangles), and 2′diF-4′N 3 -C (red squares) against wild-type (a) NiV and (b) Hendra virus (HeV) as measured by CPE determination. CPE assays were independently repeated at least 3 times for each compound for both NiV and HeV. Reduction of infectious NiV (c) and HeV (d) yield by 2′F-4′N 3 -C and 2′diF-4′N 3 -C. TCID 50 /mL values (in log scale) for each data point represent the mean of triplicate (2′diF-4′N 3 -C) or quadruplicate (2′F-4′N 3 -C) infection experiments for each concentration in the 10-point, 3-fold dilution series of each compound performed once. Dotted line indicates limit of detection. Error bars indicate standard deviation of the mean values.

M.K. Lo et al. Antiviral Research 153 (2018) 101-113 small airway epithelial cells (SAECs), which have been shown to support robust NiV replication (Escaffre et al., 2013) . For both the reporter and CPE assays which utilized the recombinant reporter NiV-GFP2AM virus, we observed potent inhibition by 2′F-4′N 3 -C, with respective EC 50 values of 0.34 and 0.56 μM (Fig. 9a-b , Table 2 ). The inhibition of both GFP and CPE could be visually observed, as treatment with 2′F-4′N 3 -C at 1.56 μM completely abolished GFP expression as well as CPE in the SAECs (Fig. 9c) . On the other hand, we observed markedly lower antiviral activity for R1479 and 2′diF-4′N 3 -C, which indicates that their respective intracellular NTP levels were likely lower than their levels observed in NCI-H358 cells.

Since filovirus-pseudotyped lentiviruses can efficiently transduce airway epithelial cells in vivo (Kobinger et al., 2001) , we proceeded to evaluate the antiviral activities of these nucleosides in SAECs against a reporter Marburg virus (MARV-ZsG) expressing a green fluorescent protein. In cells treated with serial dilutions of 2′diF-4′N 3 -C, we observed a dose-dependent inhibition of MARV infection by FFU assay; whereas R1479 and 2′F-4′N 3 -C did not show any significant inhibition ( Fig. 10a-b , Table 2 ). The comparatively higher EC 50 value for 2′diF-4′N 3 -C against MARV-ZsG in SAECs (3.59 μM) than what was observed for RAVV in NCI-H358 cells (0.73 μM) is likely due to lower intracellular NTP levels.

In this study, we characterized the antiviral properties of R1479 and its analogs 2′F-4′N 3 -C and 2′diF-4′N 3 -C using both cell-free and cellbased assays. Despite the presence of 3′-OH group in each analog, all 3 compounds behaved like conventional non-obligatory RNA synthesis chain terminators in cell-free RSV polymerase assays . In order for nucleoside analogs to retain their antiviral function inside a cell, multiple cellular kinases are required to convert them to the active triphosphate form (Ray and Hitchcock, 2009) . To better understand the cell type-dependent variability we previously observed with R1479 antiviral activity , we measured cellular levels of R1479-TP in 4 different cell lines, and observed 2 to 3fold higher levels of R1479-TP, 2′F-4′N 3 -CTP, and 2′diF-4′N 3 -CTP in NCI-H358 cells than in HeLa cells. The comparatively elevated NTP levels observed in NCI-H358 cells may be attributed to higher expression levels of uridine-cytidine kinases, which catalyze the presumed initial rate-limiting step of phosphorylating uridine and cytidine nucleosides (Van Rompay et al., 2001) . Characterizing the NCI-H358 cell line as the optimal line to use in this study highlights the importance of confirming cellular triphosphate levels when conducting antiviral screens of nucleoside analog libraries. We have observed significantly decreased antiviral activity for R1479, 2′F-4′N 3 -C, and 2′diF-4′N 3 -C in Huh7 cells against reporter EBOVs (data not shown), which is likely explained by overall lower phosphorylation levels of these cytidine analogs in this cell line (Fig. 2a) . The higher potency of 2′F-4′N 3 -C, and 2′diF-4′N 3 -C over R1479 against paramyxoviruses, however, cannot solely be attributed to NTP levels, since R1479-TP levels were higher than 2′F-4′N 3 -CTP levels in these cells (Fig. 2b) . Moreover, the change in rank order of anti-filoviral potency in the cell-based assays suggests that the differences in antiviral activity are due to differential recognition, or discrimination, of these NTP analogs by viral polymerases. Our gel-based biochemical assay using RSV polymerase provides qualitative results and informs mainly on the mechanism of action of each compound, demonstrating substrate recognition and chain termination (Fig. 1) . It does not provide enough information to rank order potencies and/or discrimination between the three nucleotides . Evaluation of these compounds in primary human SAECs confirmed the potent anti-NiV activity of 2′F-4′N 3 -C (Fig. 9 ) and the anti-MARV activity of 2′diF-4′N 3 -C (Fig. 10) . Our study did not include two other related nucleosides 2′-deoxy-2′-β-fluoro-4′-azidocytidine (RO-0622) and 2′-deoxy-2′-β-hydroxy-4′-azidocytidine (RO-9187) (Klumpp et al., 2008) because they had little to no antiviral activity against both NiV and EBOV, respectively (data not shown). Our results warrant further studies comparing the antiviral potency of these NTP analogs against recombinant paramyxovirus and filovirus polymerases, although technical challenges have precluded such work only until very Fig. 7 . R1479, 2′F-4′N 3 -C, and 2′diF-4′N 3 -C inhibit Sudan virus (SUDV). (a) Representative dose-response curves for R1479 (green circles), 2′F-4′N 3 -C (blue triangles), and 2′diF-4′N 3 -C (red squares) against SUDV (Gulu variant) using a focus forming unit (FFU) assay. FFU assays for R1479 and 2′F-4′N 3 -C were performed once, and was repeated once for 2′diF-4′N 3 -C. (b) Reduction of infectious SUDV yield (in log scale) by R1479, 2′diF-4′N 3 -C, and 2′F-4′N 3 -C. TCID 50 /mL values (in log scale) for each data point represent the mean of quadruplicate infections for each concentration in the 10-point, 3-fold dilution series for each compound performed once. Fig. 8 . R1479, 2′F-4′N 3 -C, and 2′diF-4′N 3 -C inhibit Marburgvirus Ravn virus (RAVV). (a) Representative dose-response curves of R1479 (green circles), 2′F-4′N 3 -C (blue triangles), and 2′diF-4′N 3 -C (red squares) against RAVV using an FFU assay. FFU assays were independently repeated four times for R1479, twice for 2′F-4′N 3 -C, and three times for 2′diF-4′N 3 -C. Dose response curves were fitted to the mean value of experiments performed in quadruplicate for each concentration in the 10point, 3-fold dilution series using a 4-parameter non-linear logistic regression curve with variable slope. (b) Reduction of infectious RAVV yield (in log scale) by R1479, 2′diF-4′N 3 -C, and 2′F-4′N 3 -C. TCID 50 /mL values for each data point represent the mean of quadruplicate infections for each concentration in the 10-point, 3fold dilution series of each compound performed once.

recently (Jordan et al., 2018) . The ability of these cytidine analogs to reduce henipavirus and filovirus infectious yields by over 4 log TCID 50 / mL mirrors viral inhibition by GS-441524 (a 1′-cyano-modified adenosine analog) and its phosphoramidate nucleotide prodrug GS-5734 . GS-5734 inhibited filoviruses and coronaviruses in non-human primate and mouse models, respectively, and is currently in phase 2 clinical trials for treatment of EBOV disease (EVD) (Sheahan et al., 2017; Warren et al., 2016) . Favipiravir, also known at T-705, is a broad-spectrum small molecule nucleoside precursor originally developed to treat influenza A virus; it also decreased EBOV infectious yield by 4 logTCID 50 /mL, albeit at high concentrations (1000 μM) by a yet-undefined mechanism (Baranovich et al., 2013; Oestereich et al., 2014) . BCX4430 is an adenosine nucleoside analog with variable in vitro broadspectrum activity across 8 virus families including Filoviridae, and is currently in phase 1 clinical trials for treating EVD (Taylor et al., 2016; Warren et al., 2014) . Although BCX4430 inhibits HCV polymerase similarly to conventional chain terminators and also reduces infectious filovirus yield, its mechanism of action against negative-strand viruses is unclear. While neither R1479 nor its 2′-fluoro-modified analogs are viable candidates for antiviral therapeutics due to variable incorporation by host mitochondrial RNA and DNA polymerases (Arnold et al., 2012; Clarke et al., 2015) , they provide an initial comparison of filo- Fig. 9 . 2′F-4′N 3 -C potently inhibits reporter NiV gene expression (GFP) and cytopathic effect (CPE) in human primary small airway epithelial cells. Representative dose response curves for R1479 (green circles), 2′F-4′N 3 -C (blue triangles), and 2′diF-4′N 3 -C (red squares) against recombinant reporter NiV (NiVGFP2AM) by measuring (a) GFP expression at 48 h post-infection, and by measuring (b) CPE inhibition at 72 h postinfection. Data points and error bars indicate the mean value and standard deviation of 4 biological replicates. (c) Bright field (BF) and fluorescence (GFP) microscopy of uninfected control, DMSO treated NiV-GFP2AM infected control, and 2′F-4′N 3 -C treated NiV-GFP2AM infected SAECs. Concentration of 2′F-4′N 3 -C is indicated in μM. White bar indicates distance of 500 μm. and paramyxovirus susceptibility to 4′-modified nucleosides. Our study provides evidence supporting the development of 4′-modified nucleosides with near-equivalent potency not only against 3 Mononegavirales order families, but also against the positive-sense Flaviviridae family. Developing a small-molecule, broad-spectrum therapeutic to treat phylogenetically divergent viral infections that share significant epidemiological and clinical overlap (e.g., EBOV and yellow fever virus; NiV and Japanese encephalitis virus) would benefit clinicians with no access to rapid diagnostics amidst an outbreak of these serious viral infections. Table 2 Mean antiviral activity of R1479, 2′F-4′N 3 -C, and 2′diF-4′N 3 -C in primary human small airway epithelial cells. EC 50 , 50% effective inhibition concentration; SI, selective index = EC 50 /CC 50 ; REP, reporter; CPE, cytopathic effect; FFU, focus-forming unit; ND, not determined; Rec, recombinant. Mean values with ± standard deviation values were derived from a minimum of 2 independent experiments performed in biological quadruplicate. 

Development of a reverse genetics system to generate a recombinant Ebola virus Makona expressing a green fluorescent protein

Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides

Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease

Hendra virus and Nipah virus animal vaccines

Outbreaks Chronology: Ebola Virus Disease

A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels

Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir

Discovery of beta-D-2'-deoxy-2'-alpha-fluoro-4'-alpha-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases

Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2'-fluoro-4'-chloromethyl-cytidine triphosphate

Henipavirus pathogenesis in human respiratory epithelial cells

Structure-activity relationships of nucleoside analogues for inhibition of tickborne encephalitis virus

Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody

Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection

4'-Azidocytidine (R1479) inhibits henipaviruses and other paramyxoviruses with high potency

Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya

Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase

2'-deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups

The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture

Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo

Containing a haemorrhagic fever epidemic: the Ebola experience in Uganda

GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep. 7

Evaluation of luciferase and GFP-expressing Nipah viruses for rapid quantitative antiviral screening

Epidemiology of henipavirus disease in humans

Evaluation of Ebola virus inhibitors for drug repurposing

The ongoing evolution of antibody-based treatments for Ebola virus infection

Ebola virus vaccines -reality or fiction?

Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients

A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients

The respiratory syncytial virus polymerase has multiple RNA synthesis activities at the promoter

Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

Metabolism of antiviral nucleosides and nucleotides

A simple method of estimating fifty percent endpoints

Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates

Complete genome sequence of an Ebola virus (Sudan species) responsible for a 2000 outbreak of human disease in Uganda

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4'-azidocytidine against hepatitis C virus replication: the discovery of 4'-azido-2'-deoxy-2'-fluorocytidine and 4'-azido-2'-dideoxy-2',2'-difluorocytidine

Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479

BCX4430-A broadspectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease

Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola

Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening

Phosphorylation of uridine and cytidine nucleoside analogs by two human uridinecytidine kinases

Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection

Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection

Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430

Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems

Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium

We thank the nucleoside chemistry group at Alios for synthesizing the compounds and their NTPs, and Julian Symons and Leo Beigelman from Alios for supporting this work. We thank Mike Flint and Tatyana Klimova for helpful comments in reviewing the manuscript. We also thank Cesar A. Albarino for providing the MARV-ZsG virus. The findings and conclusions in this report are those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention. This work was financially supported by CDC core funding.

Supplementary data related to this article can be found at http://dx. doi.org/10.1016/j.antiviral.2018.03.009.